GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » EPS (Diluted)

Moleculin Biotech (Moleculin Biotech) EPS (Diluted) : $-15.30 (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech EPS (Diluted)?

Moleculin Biotech's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-5.25. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.30.

Moleculin Biotech's EPS (Basic) for the three months ended in Dec. 2023 was $-5.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.30.

Moleculin Biotech's EPS without NRI for the three months ended in Dec. 2023 was $-4.68. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.77.

During the past 3 years, the average EPS without NRIGrowth Rate was 21.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 24.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Moleculin Biotech's highest 3-Year average EPS without NRI Growth Rate was 37.80% per year. The lowest was -1.90% per year. And the median was 21.30% per year.


Moleculin Biotech EPS (Diluted) Historical Data

The historical data trend for Moleculin Biotech's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech EPS (Diluted) Chart

Moleculin Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -29.25 -26.40 -8.85 -15.30 -15.15

Moleculin Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.60 -4.20 -3.00 -2.85 -5.25

Competitive Comparison of Moleculin Biotech's EPS (Diluted)

For the Biotechnology subindustry, Moleculin Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's PE Ratio falls into.



Moleculin Biotech EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Moleculin Biotech's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-29.769-0)/1.966
=-15.14

Moleculin Biotech's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-10.269-0)/1.979
=-5.19

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moleculin Biotech  (NAS:MBRX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Moleculin Biotech EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Moleculin Biotech (Moleculin Biotech) Business Description

Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.
Executives
Jonathan P. Foster officer: Exec. Vice President and CFO 2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp director, 10 percent owner, officer: Chairman and Acting CEO 1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco director PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker 10 percent owner, officer: President and COO
Michael D Cannon director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth officer: Chief Financial Officer 2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380